# PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN)

> **NCT03671967** · PHASE4 · RECRUITING · sponsor: **Rambam Health Care Campus** · enrollment: 1084 (estimated)

## Conditions studied

- Beta Lactam Resistant Bacterial Infection
- Enterobacteriaceae Infections
- Bacteremia

## Interventions

- **DRUG:** Piperacillin/tazobactam
- **DRUG:** Meropenem

## Key facts

- **NCT ID:** NCT03671967
- **Lead sponsor:** Rambam Health Care Campus
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-05-01
- **Primary completion:** 2027-01-01
- **Final completion:** 2027-04-01
- **Target enrollment:** 1084 (ESTIMATED)
- **Last updated:** 2025-08-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03671967

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03671967, "PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03671967. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*